Loading...
Market
Will Wegovy capture more than 10% market share in China by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official sales reports or market research from reliable industry sources
Story
Novo Nordisk's Wegovy Weight-Loss Drug Approved in China, Shares Rise 1.8% Pre-Market
Jun 25, 2024, 10:35 AM
Novo Nordisk's weight-loss drug Wegovy has been approved for long-term weight management in China. The approval by China's National Medical Products Administration, announced on Tuesday via the company's official WeChat account, will allow Novo Nordisk to market Wegovy in the world's second-largest economy, which has the highest number of overweight or obese people. Wegovy, also known as semaglutide, claims to help reduce body weight by 17%, or an average of 16.8 kg. Initially, the company will focus on patients paying out-of-pocket for the weekly injectable drug. This approval is significant as Novo Nordisk faces a tight timeline with its semaglutide patent set to expire soon. Novo Nordisk has also promised to prioritize existing patients amid shortages. The company's shares rose by 1.8% pre-market following the announcement.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Price competitiveness • 25%
Efficacy and safety profile • 25%
Marketing and distribution • 25%
Regulatory support • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Zepbound gains >10% market share over Wegovy • 25%
Zepbound gains 0-10% market share over Wegovy • 25%
Wegovy maintains current market share • 25%
Wegovy gains market share over Zepbound • 25%
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
Shanghai • 25%
Beijing • 25%
Guangzhou • 25%
Other • 25%
